<?xml version='1.0' encoding='utf-8'?>
<document id="22426579"><sentence text="Limited end-user knowledge of methotrexate despite patient education: an assessment of rheumatologic preventive practice and effectiveness."><entity charOffset="30-42" id="DDI-PubMed.22426579.s1.e0" text="methotrexate" /></sentence><sentence text="Methotrexate (MTX) is a first-line disease-modifying agent and anchor drug for biologic therapy used in rheumatoid arthritis and other inflammatory rheumatic disorders"><entity charOffset="0-12" id="DDI-PubMed.22426579.s2.e0" text="Methotrexate" /><entity charOffset="14-17" id="DDI-PubMed.22426579.s2.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.22426579.s2.e0" e2="DDI-PubMed.22426579.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22426579.s2.e0" e2="DDI-PubMed.22426579.s2.e1" /></sentence><sentence text=" Adverse effects are a common cause of drug discontinuation and include preventable serious incidents that may result in patient harm or death" /><sentence text="" /><sentence text="The objective of this study was to audit adherence by health professionals to national and international guidelines for patient education and risk reduction in patients prescribed MTX for inflammatory rheumatic diseases"><entity charOffset="180-182" id="DDI-PubMed.22426579.s5.e0" text="MTX" /></sentence><sentence text="" /><sentence text="A combination of interviews, case record reviews, and self-administered patient knowledge questionnaires with individual patient feedback was used" /><sentence text=" The setting was the rheumatology outpatient department of a district general hospital" /><sentence text="" /><sentence text="Fifty-one patients participated in the audit" /><sentence text=" The mean age was 58" /><sentence text="6 (SD, 13" /><sentence text="1) years and median duration of disease was 3" /><sentence text="7 years (interquartile range, 1" /><sentence text="7-7" /><sentence text="6 years)" /><sentence text=" Nurse-led patient education was documented at baseline for 94" /><sentence text="1% of participants" /><sentence text=" Despite this, only 11" /><sentence text="8% of participants recognized the potentially lethal drug-drug interaction with trimethoprim/Septrin (co-trimoxazole), and less than 60"><entity charOffset="80-92" id="DDI-PubMed.22426579.s20.e0" text="trimethoprim" /><entity charOffset="93-100" id="DDI-PubMed.22426579.s20.e1" text="Septrin" /><pair ddi="false" e1="DDI-PubMed.22426579.s20.e0" e2="DDI-PubMed.22426579.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22426579.s20.e0" e2="DDI-PubMed.22426579.s20.e1" /></sentence><sentence text="8% recognized possible major adverse effects related to MTX"><entity charOffset="56-62" id="DDI-PubMed.22426579.s21.e0" text="MTX" /></sentence><sentence text=" Although lifestyle implications relating to alcohol consumption and pregnancy/breast-feeding were recognized by the majority, only 52"><entity charOffset="45-52" id="DDI-PubMed.22426579.s22.e0" text="alcohol" /></sentence><sentence text="9% of males were aware of recommendations in relation to conception" /><sentence text=" Univariable and multivariable analyses identified male sex, not speaking English as a first language, and a longer duration of therapy as predictors of lower levels of patient knowledge" /><sentence text="" /><sentence text="Despite consistent baseline patient education, end-user knowledge and awareness pertinent to MTX safety are limited"><entity charOffset="93-99" id="DDI-PubMed.22426579.s26.e0" text="MTX" /></sentence><sentence text=" Good-quality written information in the most appropriate language, patient feedback on educational programs, follow-up testing of patient knowledge, and targeted reeducation are recommended to address individual deficiencies in core knowledge" /><sentence text="" /></document>